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ABSTRACT" The use of fluorescence in situ hybridization (FISH) for the purpose of repeated follow-up 
examination of bone marrow samples from 38 leukemia patients was investigated. On the basis of con- 
ventional cytoge;3etic analysis, patients with acute leukemia whose leukemic ells carried numerical 
chromosomal aberrations were selected and followed with repetitive DNA probes that specifically 
hybridize to one chromosome type. Repeated cytogenetic metaphase analyses would have been labori- 
ous and not sensitive or quantitative nough to follow declining numbers of aberrant cells. FISH, as 
an interphase cytogenetic technique, provides a rapid and simple alternative with high sensitivity. 
Although FISH data before and after chemotherapy were & agreement with bone marrow cytology in 30 
of 38 patients, discrepancies were noticed in specific cases. These could be explained by the presence of 
cytogenetically distinct subclones that behave differently during treatment, he presence of differenti- 
ated leukemic ells, changes in the chromosomal constitution caused by clonal relapse, or the fact that 
a numerical aberration is found by conventional chromosome banding analysis while the target region 
to which the probe is directed is still present in the nucleus as a diploid set. 
INTRODUCTION 
The ability to monitor leukemia patients for the presence 
of residual eukemic cells depends on the characteristics 
of the leukemic cells and the choice of the detection 
method. Parameters have to be chosen that allow discrimi- 
nation of the leukemic cells from their normal counter- 
parts. One way of discr:[minating normal from aberrant 
cells is by fluorescence in situ hybridization (FISH) on 
interphase cells. FISH allows the recognition of the cen- 
tromeres on the chromosomes as clearly localized and 
brightly fluorescent spots in metaphase spreads or in 
nuclei [1-4]. The number of centromeres present in the 
cell will be reflected by the number of fluorescent spots 
per nucleus. This provides ameans to enumerate he copy 
number of chromosomes [1, 4-8]. For this reason FISH has 
developed as a rapid and relatively accurate alternative to 
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conventional cytogenetic analysis [9-11]. In combination 
with immunophenotyping, it can give information about 
cell lineage, the lymphocyte subpopulation, and the geno- 
type from serially followed sex-mismatched bone marrow 
transplants or demonstrate he presence of leukemia cells 
with the host phenotype [12]. 
Cytogenetically, a considerable fraction of the leukemia 
cases can be discriminated on the basis of numerical chro- 
mosomal aberrations (gain or loss of one or more chromo- 
somes). Numerical aberrations occur in approximately 
54% of the patients with acute myelocytic leukemia 
(AML). In 30% of children and 5% of adults with acute 
lymphocytic leukemia (ALL} a hyperdiploid karyotype is 
found. A near-haploid karyotype is found in 1% of the 
ALL cases. In chronic myelocytic leukemia (CML) in blast 
crises numerical chromosomal changes are observed in 
70% of the cases [13, 14]. 
The fact that a considerable number of leukemias how 
numerical chromosomal berrations, the speed and ease of 
performance, and the relative accuracy has made FISH an 
attractive method for patient monitoring. In this study we 
have examined the feasibility of the FISH procedure for 
the follow-up of leukemia patients. For our study we 
selected patients with numerical chromosomal berrations 
in their leukemic cells as judged by conventional cytoge- 
netic analysis. They were followed with FISH and cytol- 
ogy from the time of diagnosis through the phase of 
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complete remission (detection of minimal residual dis- 
ease) until  relapse, if this occurred. Although in general a 
clear correlation was found between bone marrow cytol- 
ogy, conventional cytogenetic analysis, and FISH, in sev- 
eral cases unexpected results were obtained. This report 
emphasizes these specific discrepancies and discusses 
implications for future routine bone marrow analysis of 
leukemia patients with FISH. 
MATERIALS AND METHODS 
Samples 
Bone marrow samples were obtained by an aspiration 
from the iliac crest. Cytology was performed after May- 
Grfinwald Giemsa staining of the bone marrow smears. 
Bone marrow for the FISH study was collected in sterile 
heparinized flasks. During the process of cell separation 
the samples were kept at 4°C. The red cells were lysed by 
addition of excess buffer, consisting of 155 mM NH4C1, 0.1 
mM EDTA, and 11.9 mM NaHCO3. After centrifugation, 
the nucleated cells were washed twice in Hanks' HEPES- 
buffered balanced salt solution. 
Fluorescence in Situ Hybridization 
Cell suspensions were treated with hypotonic buffer (0.075 
M KC1) for 10 minutes at room temperature. Suspensions 
were centrifuged and the cells were fixed with methanol/ 
acetic acid under continuous vortexing. Fixation was 
repeated three times. After fixation the cell suspensions 
were dropped onto cleaned microscope slides and the area 
was marked with a diamond-tipped pen. 
Complete plasmid with insert was labeled with biotin- 
16-dUTP using the nick-translation procedure [15]. Probes 
used in this study were chosen on the basis of the aberra- 
tions found in the patients and are listed in Table 1 [16- 
23]. All probes recognized chromosome-specific repetitive 
DNA sequences. The average probe fragment sizes after 
nick-translation ranged from 200-400 base pairs. 
Directly before the hybridization procedure, the slides 
were placed in ethanol for at least 60 minutes at room tem-  
perature and air dried. Slides were then incubated in 0.1 
M HC1/0.1% Tween-20 for 15 minutes to remove matrix 
and histone proteins and to improve accessibility of the 
nuclei for the DNA probe. 
Denaturation of the target DNA was accomplished by 
placing the slides in 70% formamide/2 x SSC pH 7 at 
70°C for 2 minutes followed by dehydration i  an ice-cold 
ethanol series of 70%, 85% and 100%. The hybridization 
mixture consisted of i ~g/mL probe DNA, 0.1 mg/mL son- 
icated herring sperm DNA, 0.1% Tween-20, 10% dextran 
sulfate, and 2 × SSC in 50% formamide at pH 7. Probes 
were denatured in the hybridization mixture for 10 min- 
utes at 90°C and placed on ice immediately. Approxi- 
mately 12 ~L of this denatured hybridization mixture was 
pipetted onto the marked area of the microscope slide. 
The area was covered with a plastic coverslip and the 
slide was placed in a humid atmosphere at 37°C for 4 
hours. After hybridization, slides were washed 3 times for 
2 minutes in 2 × SSC followed by a stringent washing in 
50% formamide in 2 × SSC. Five minutes at 45°C was 
Table I Mean number of fluorescent spots per nucleus as 
observed by fluorescence in situ hybridization 
on peripheral blood cells from healthy male and 
female individuals (350 nuclei were scored per 
probe) 
Frequency of fluorescent spots 
Probe for per nucleus (%)~ 
chromosome' :  0 1 2 3 Other b
(n = 5males) 
7 0.6 2.4 93.6 0.7 2.7 
0.5 1.1 2.0 0.3 1.0 
8 0.8 2.7 93.3 1.0 2.2 
0.8 1.1 1.9 0.7 0.5 
9 0.6 1.1 96.6 0.4 1.3 
0.4 0.2 1.0 0.5 1.9 
10 0.3 1.7 95.6 0.4 2.0 
0.4 0.9 1.9 0.1 0.8 
11 0.3 2.0 94.8 0.6 2.3 
0,5 0.7 2.1 0.5 1.5 
17 0,7 2.5 93.2 0.6 3.0 
0,6 0.9 2.6 0.4 2.0 
18 0.3 1.4 94.9 0.6 2.8 
0.2 0.2 2.1 0.5 2.2 
X 0.9 97.7 0.2 0.0 1.2 
0,7 1.0 0.3 0.0 0.9 
Y 0.6 98.7 0.2 0.0 0.5 
0.3 0.4 0.3 0.0 0.4 
(n = 4 ~males) 
X 0.6 1.5 95.2 0.6 2.1 
0.2 0.2 0.8 0.3 1.0 
Y 99.6 0.2 0.0 0.0 0.2 
0.5 0.2 0.0 0.0 0.3 
a Average values are given. Standard deviation i italics. 
b This column shows the percentage of nuclei that did not display adis- 
crete number of spots. In this group unclassifiable nuclei and split spots 
are taken together. 
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used routinely but with probes known for high nonspe- 
cific binding, stringency was increased by either increase 
of the temperature, formamide concentration, or time of 
washing. Slides were washed in 2 x SSC and finally 
placed in 4 × SSC/0.05% Triton-x-100 (SSC-T). 
Visualization of the biotin-labeled probe binding was 
accomplished by incubation of the slides with Avidin- 
FITC (Av-FITC) conjugate (Vector, Burlingame, CA), 5 ~g/ 
mL in 5% non-fat dry milk in SSC-T with 0.002% sodium- 
azide, for 20 minutes at 37°C. Slides were washed three 
times for 2 minutes each with SSC-T buffer. In those cases 
where amplification of the signal was required, slides 
were incubated with biotin-labeled goat-anti-Avidin (Vec- 
tor), 5 p.g/mL in 5% non-fat dry milk, for 20 minutes at 
37°C. After washing, the Av-FITC incubation step was 
repeated. Nuclear DNA was counterstained with propid- 
ium-iodide (1 ~g/mL) in Slowfade (Molecular Probes, 
Eugene, OR). 
Scoring of Fluorescent Spots 
A Zeiss Axioskop-20 microscope was used. Screening of 
the slides was performed with a 63 x objective lens. Every 
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nucleus in the field of view was taken into account. Per 
slide, 300-500 nuclei were scored. When nuclei could not 
be classified to a group with a discrete number of spots 
they were scored as "1 or 2," or "split spots," i.e., fluores- 
cent spots were seen that seemed to be split in two, thus 
appearing as two smaller spots close together each with 
half the fluorescence intensity of a single spot. Each subse- 
quent sample was scored per patient by the same observer. 
Cont ro l s  
For each probe in this study control values were derived 
from the peripheral blood from five healthy male individ- 
uals. In addition, four healthy female samples were tested 
with X and Y probes only 
RESULTS 
Table i shows the performance of the probes used in this 
study. When tested on peripheral blood from five healthy 
men and four healthy women none of the probes reached 
100% diploidy when the number of FISH signals per 
nucleus was counted. For the autosomes, the two spots 
that can be expected per nucleus are observed in 93.2- 
96.6% of the cells. For the sex chromosomes (one spot per 
nucleus for both X and Y chromosome) in male cells the 
values are 98.7%. In female cells (two or zero spots for X 
and Y probes, respectively), 95.2% and 99.6% are the val- 
ues of the expected number of spots in healthy cells. This 
phenomenon is considered to determine the lower detec- 
tion level of the method. 
The FISH results performed on the bone marrow cells 
from the leukemia patients could be classified into three 
groups: one in which bone marrow cytology and FISH 
showed good correlation, a second group in which the leu- 
kemic cell number as determined by FISH was lower 
when compared to the number of blast cells found by 
cytology, and a third group in which the number of leuke- 
mic cells as determined by FISH was higher when com- 
pared to the number of blasts. Furthermore, with multiple 
hybridizations performed in some cases with different 
repetitive DNA probes, it was shown that noncorrelating 
fluctuations exist when different probes were tested in one 
patient, 
From 38 patients with acute leukemia, bone marrow 
samples were investigated at diagnosis or thereafter. In 30 
cases the FISH findings were in accordance with what 
Table 2 Discrepancies found between FISH and bone marrow cytology in eight patients 
Patient Diagnesis 
1 AML M1 % of cells with +10 43 0 0 0 0 
% of blasts 90 16 14 4 3 
Time (months) 0 1 2.5 4 5 
2 ALL % of cells with +17 33 38 
% of cells with +X+X 72 54 
% of cells with +Y 74 55 
% of blasts 95 95 
Time (months) 0 1 
3 RAEB % of cells with - 7 68 4 17 17 
% of cells with -17 5 5 2 2 
% of blasts 18 0 ND Biopsy 
Time (months) 17 18.5 19 20 
4 AML M2 % of cellswith +8+8 0 0 0 0 0 
% of blasts 6 5 4.6 0.8 3.3 
Time (months) 5 6 10 16 20 
5 AML Ni2 % of cells with -Y 98 11 1 5 3 
% of blasts 44 4 5 0 3 
Time (months) 0 1.5 3 4 4.5 
6 AML lvll % of cells with -7 1 1 5 
% of cells with +8 37 1 0 
% of blasts 35 5 3 
Time (months} 0 1.5 3 
7 ALL % of cells with + 7 1 
% of cells with +8 13 
% of cells with +11 25 
% of cells with +18 2 
% of cells with +Y 15 
% of blasts ND 
Time (months) 14 
8 MM a % of cells with + 7 78 
% of cells with - 8 2.4 
% of cells with +9 81 
% of blasts ND 
Time (months) 5 
0 0 0 
3 19 8 
5.5 9 9.5 
a MM, Multiple rnyeloma. Unexpected values are in bold. 
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could be expected on the basis of the phase of the disease 
and bone marrow cytology. In general, both FISH data and 
cytology data showed a sharp decrease in the percentage 
of aberrant cells or blasts after the first course of chemo- 
therapy (data not shown). 
In Table 2 the results are given from eight patients in 
which a clear discrepancy exists between conventional 
cytogenetic analysis, bone marrow cytology, and FISH 
results. In this table time indicates the timepoints after 
diagnosis at which samples were collected for FISH analy- 
sis. Guided by conventional cytogenetic analysis, probes 
were chosen that allowed recognition of numerical aberra- 
tions. These aberrations are indicated in column 3. In the 
corresponding rows the percentages of cells that showed 
the expected aberrations as judged by FISH are indicated 
at the various timepoints. The data points for which dis- 
crepancies exist between bone marrow cytology (percent- 
age of blast) and FISH or among multiple FISH results are 
in bold. At those timepoints where bone marrow cytology 
data were not available this is indicated by ND in Table 2. 
Detailed cytogenetic analyses of these eight patients at the 
time of diagnosis is presented in Table 3. 
In patient 1, a 90% blasts cell count was observed in 
the bone marrow at diagnosis. This was much higher than 
the percentage of cells with a trisomy for chromosome 10 
found by FISH (43%). After the first course of chemother- 
apy, the cells with a trisomy 10 as observed by FISH disap- 
peared. Yet, only a partial remission was achieved as 
judged by cytologic analysis (16% blasts). From this time- 
point with FISH no aberrant cells could be detected. The 
second treatment course did not further educe the number 
of blasts in the bone marrow (14%). A complete remission 
was achieved only after the third course of chemotherapy 
(4 months after diagnosis). None months after diagnosis an 
increase in blasts was observed (19%), while the analysis 
for trisomy 10 with FISH remained negative. 
In the leukemic cells of patient 2 multiple numerical 
aberrations were found. This patient was tested with 
probes for chromosome 17, X, and Y. Two timepoints were 
available. For each timepoint and for each probe the per- 
centage of cells with aberrant FISH signals appeared to be 
lower than the percentage ofblast found by cytology. 
In patient 3, with a monosomy for chromosome 17 
found by conventional cytogenetic analysis in 19 of 25 
metaphases with aberrant karyotype, a similar observation 
was made. At 17 months after diagnosis the bone marrow 
contained 5% of cells with a monosomy 17 when ana- 
lyzed by FISH but 18% blasts by cytology. 
In patient 4, who was diagnosed with a tetrasomy for 
chromosome 8, FISH with the centromere probe for chro- 
mosome 8 did not reveal cells with three or four spots dur- 
ing the entire period of follow-up. One month after the 
fourth chemotherapy course, at t = 5 months (earlier sam- 
ple points were not available for FISH), 6% blasts at this 
stage indicated a partial remission. Thereafter a continu- 
ous complete remission was observed (less than 5% 
blasts). 
In patient 5 the percentage of aberrant cells that was 
observed at diagnosis with FISH was much higher than 
the percentage ofblasts found with cytology, i.e., 98% vs. 
44%, respectively. The percentage of cells characterized 
by -Y  4 and 4.5 months later, after chemotherapy, was 5 
and 3, respectively, which is well above the lower detec- 
tion level of this probe (see Table 1). Blast cell frequencies 
less than 5% indicate morphologic complete remission at 
these timepoints. Proof of imminent relapse was not 
Table 3 Detailed cytogenetic analysis of eight patients in which no correlation was found between umerical 
chromosomal berrations as measured by FISH and bone marrow cytology 
Patient number 
(age at diagnosis) Diagnosis Karyotype at diagnosis 
1 AML M1 47,XX,+ 10,t(11;17)(q23;q24)[37] 
(25) 
2 ALL 46,XY,t(2;1O)(q32.2;q11)c[19] 
( 1 8 )  56,XY,+X,+X,+Y,t(2;10)c+4,+5,+6,+ 14,+17,+21,+21119] 
3 RAEB 45,XY,der(5)t(5;17)(q21;q12),- 17 ] 
(56) 44,XY,idem,- 7,[14] 
43,XY,idem,- 7,- 14,der(19)t(14;19)(q13;q13)[3] 
46,XY[6] 
48,XX,+ 8,+8,t(11;17)(p15;q23)[8] 
46,XX[10] 
45,X,-Y,t(8;2;16;21)(q22;q32;q13;q22)[31] 
4 AML M2 
(70) 
5 AML M2 
(50) 
6 AML M1 
(45) 
7 ALL 
(17) 
8 MM 
(45) 
46,XY,t(1;15)(p21;23),t(3;5)(q23;q12),ins(4;12)(q28;p?),dic(5;17)(qll;p11),der(7)t(7;18;14) 
(7q11;18q12-~q23;14q12--~qter),+ 8,- 14,del(18)(q12q23),add(19)(q23),+ 21132] 
46,XY[8] 
60-68 ~3n>,XY,add(2)(p16),- 3,-516],add(9)(q34),+ 10, 12,- 13,- 16,- 17,+del(18)(q21), 
- 20,- 21,+ 22,+ 2mar[cpl0] 
46,XY[5] 
50,XY,del(2q),+ 7,- 8,+9,+ 11,der(12)t(8;12)(q?;p?),- 13,+15,der(16)t(1;16)(q21;q?),+ 17 
+mar[4] 
46,XY[11] 
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obtained since this patient died of a pneumonitis shortly 
after the last bone marrow sample was taken. 
The same phenomenon was observed in patient 3. In 
this patient, 68% of the cells carried a monosomy for chro- 
mosome 7 at 17 months after initial diagnosis, while at 
this stage 18% blast cells were found in the bone marrow. 
Chemotherapy was given and after an initial decrease in 
numerically aberrant cell numbers, again an increase was 
observed after 19-20 months, which concurs with the rise 
of the percentage of blast cells in the bone marrow as 
judged by bone marrow biopsy. At 19 months an exact per- 
centage of blasts could not be given; at 20 months, biopsy 
indicated an increase in the percentage of blasts ranging 
between 10% and 20%. 
In a number of patients multiple numerical aberrations 
allowed the investigation with more than one chromo- 
some-specific probe. In patients 2, 3, 7, and 8, the fluctua- 
tions that were observed in percentages of cells with 
aberrant numbers of spots for the various probes that were 
used did not correlate with each other. In patient 3, in con- 
trast to the observations with the chromosome 7-specific 
probe, FISH with a probe specific for chromosome 17 
(which was reported to be the second numerical aberra- 
tion) showed low numbers of aberrant cells at all time- 
points and no increase a~: the time of relapse. 
DISCUSSION 
Metaphase cytogenetic analysis provides detailed infor- 
mation about the karyotype of a limited number of cells. 
Interphase cytogenetic analysis uch as FISH, on the other 
hand, provides limited i.~3formation about he karyotype of 
a large number of cells. No short-term cultures are required, 
analysis of the metapha~,;es and recognition of the banded 
chromosomes i  not ne~zessary, and due to the fact that 
interphase nuclei are studied that are derived directly 
from the patient, selective outgrowth of subpopulations 
during short-term culture is prevented and a representa- 
tive percentage ofaberrant cells as present in the patient is 
obtained. The number of nuclei that can be analyzed rou- 
tinely with FISH is at le~Lst tenfold higher than the number 
of metaphases that is routinely analyzed with conven- 
tional cytogenetic analysis. Therefore FISH allows rapid 
quantitative analysis and follow-up of patient material 
from diagnosis through complete remission. 
The presence of cells with an aberrant number of spots 
in healthy individuals sets the threshold for the lower 
detection level of aberrant cells in leukemia samples. Dif- 
ferent statistical tests have been evaluated to determine 
the number of cells that has to be counted to observe sig- 
nificant differences between control samples and samples 
with aberrant cells [24:]. Once approximately 400-500 
cells per sample are analyzed, the lower detection level is 
on the order of 1-5%. In this study, bone marrow was ana- 
lyzed that was derived from patients during and after 
remission-induction therapy. Whether FISH values obtained 
from bone marrow regenerated after chemotherapy can be 
compared to the peripheral blood values from healthy 
individuals remains questionable. The treatments hat the 
patients undergo can very well be of influence on the level 
of so-called false positive or negative signals in such bone 
marrow cells. Comparing our control studies (Table 1) 
with reports by others [25, 26], it can at least be concluded 
that our FISH methodology yields comparable r sults. 
To be able to reduce the detection level additional 
parameters are required. Such can be performed when 
FISH is combined with flow sorting. Until now this tech- 
nique has worked only in sex-mismatched bone-marrow- 
transplanted patients where a discrimination can be made 
on the basis of the sex chromosomes [27]. 
In our study of 38 patients, we found that FISH data 
were generally in agreement with data obtained by cytol- 
ogy. Nevertheless, ome patients had higher while others 
had lower numbers of leukemic cells, as determined by 
FISH, than the percentage of blasts counted in the bone 
marrow smears. The presence of a higher percentage of 
aberrant cells, as judged by FISH, in patients that morpho- 
logically are in complete remission (less than 5% blasts), 
can only be explained by the fact that cells that have lost 
their blast-like appearance carry the numerical aberration 
that is detected by FISH. A lower number of aberrant cells, 
as determined by FISH, can occur when the conventional 
cytogenetic analysis indicates a specific numerical aberra- 
tion while the target region for the probe is not involved 
and therefore still present in the nucleus as a diploid set. 
In addition, subclones with specific numerical aberrations 
can selectively be eliminated by chemotherapy in case 
they are more sensitive to the treatment. Furthermore, new 
clones may appear at relapse. Finally, blood taken with 
the bone marrow aspiration for FISH might cause a slight 
underrepresentation of the percentage ofblasts. The cases 
from our studies illustrate these points and are discussed 
in further detail below. 
In patient 1 at diagnosis, the percentage of cells carry- 
ing a trisomy for chromosome 10 as determined by FISH is 
almost wice as low as the percentage of blasts found in 
the marrow. This observation strongly suggests the pres- 
ence of at least two subclones in the patient, of which one 
is carrying a trisomy for chromosome 10. Nevertheless, 
conventional cytogenetic analysis revealed an extra chro- 
mosome 10 in all the analyzed metaphases. Since conven- 
tional cytogenetics i  based on a smaller number of cells 
and since only the dividing fraction can be studied, the 
nontrisomy-containing subpopulation of the leukemic 
cells might have remained unnoticed. In subsequent mar- 
row studies the percentage of cells with a trisomy 10 as 
determined with FISH dropped and remained at an unde- 
tectable level while the cytology data revealed the pres- 
ence of blast cells at several stages during the follow-up 
period. Apparently, the trisomy-lO-containing leukemic 
subclone was more sensitive to the chemotherapy applied 
and was therefore radicated. 
In contrast, the diagnosis ample of patient 5, with a 
loss of the Y chromosome in all leukemic cells, shows a 
twofold higher amount of aberrant cells according to the 
FISH method, as compared to cytology. Also, at 1.5 
months after diagnosis, when the patient had reached a 
complete remission (4% blasts in the bone marrow), 11% 
of the bone marrow ceils showed a loss of the Y chromo- 
some. The only explanation for the discrepancy between 
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the number of -Y  cells by FISH and the number of blasts 
in the bone marrow is that differentiated leukemic ceils 
are present. This is often observed in these types of leuke- 
mia with a translocation i volving chromosomes 8 and 21. 
The question whether these cells are fully differentiated or
still retain leukemic potential remains unsolved. 
Patient 3, characterized by a monosomy 7 and 17, 
showed a phenomenon similar to that observed in patient 
5. When a probe specific for chromosome 7 was used 17 
months after diagnosis, the number of aberrant cells found 
with FISH was higher than the amount of blasts in the 
bone marrow at that timepoint. Striking is the fact that the 
fluctuation in the frequency of cells carrying a monosomy 
17 correlated neither with the fluctuations in the percent- 
age of blast cells nor with the percentage of cells with a - 7 
found by FISH at the same timepoints. Either the percent- 
age of cells carrying the -17  is too small to observe signif- 
icant fluctuations in cell numbers, or the centromere gion 
of chromosome 17 is present and therefore in situ hybrid- 
ization on interphase nuclei, applying the probe for the 
c~-satellite DNA from chromosome 17, results in two fluo- 
rescent spots. 
The karyotype analysis of patient 6 initially revealed 
the loss of one chromosome 7. This was not in concor- 
dance with the percentage of cells carrying the trisomy for 
chromosome 8. In a later stage it was found by chromo- 
some painting on metaphases from this patient hat a part 
of chromosome 7 including the centromere was present 
(indicated as der(7) in Table 3). 
FISH is a valuable tool for the sequential analysis of 
bone marrow samples from leukemia patients whose leu- 
kemic cells carry numerical chromosomal aberrations. 
The speed and ease with which FISH can be performed 
make it an attractive technique for the assessment of treat- 
ment efficacy. The FISH method, in particular, is valuable 
on top of morphologic riteria in those leukemias where 
no other specific characteristics are available to distin- 
guish leukemic ells from normal marrow cells. Discrepan- 
cies between FISH and cytology add valuable information 
and may be helpful in understanding the disease progres- 
sion but are at the same time a potential source of errone- 
ous conclusions. This paper demonstrates that care should 
be taken with respect to the choice of probes and that 
results should be interpreted with caution. FISH as it is 
used in this study depends on conventional cytogenetic 
analysis for the proper choice of probes. Both methods 
should therefore be used as supplements o each other. 
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